SAB

Maxcom Telecomunicaciones announces that Transtelco Acquisition III today initiated a mandatory acquisition tender offer

Friday, September 24, 2021 - 3:01pm

MEXICO CITY, Sept. 24, 2021 /PRNewswire/ -- Maxcom Telecomunicaciones S.A.B. de C.V. (BMV: MAXCOM A, OTC: MXMTY) ("Maxcom" or the "Company") announces that Transtelco Acquisition III, S. de R.L. de C.V. (the "Offeror"), today initiated, in accordance with the Mexican Stock Exchange Act (Ley del Mercado de Valores or "LMV") and the General Regulations for Issuers and Other Participants of the Stock Exchange (Disposiciones de Carácter General Aplicables a Emisoras y a Otros Participantes del Mercado de Valores (the "Regulations") a mandatory acquisition tender offer (the "Equity Tender Offer") to acquire through Bolsa Mexicana de Valores, S.A.B. de C.V., S.A.B. de C.V., S.A.B. de C.V., up to all of the shares representing the capital stock of the Company, which represent 276'471,081 ordinary, nominative, without par value, subscribed and fully paid series "A" shares, at a purchase price of $2.20 (two Pesos 20/100, Mexican pesos), per share. 

Key Points: 
  • de C.V. (BMV: MAXCOM A, OTC: MXMTY) ("Maxcom" or the "Company") announces that Transtelco Acquisition III, S. de R.L.
  • The Notes Tender Offer and Consent Solicitation will remain in effect until October 21, 2021 unless extended at the request of Transtelco.
  • Furthermore, the successful conclusion of the Equity Tender Offer is conditioned upon the successful completion of the Notes Tender Offer and vice versa, among other conditions.
  • For more information on the Equity Tender Offer, the Notes Tender Offer, and the Consent Solicitation, please visit the Company's website: http://ri.maxcom.com/ .

Tubulis Establishes Scientific Advisory Board with Leading ADC Drug Development and Oncology Experts

Thursday, September 23, 2021 - 10:00am

Tubulis today announced the formation of a Scientific Advisory Board (SAB) with the appointment of international industry experts in the development of antibody drug conjugates (ADCs) and in-depth knowledge in the therapeutic areas of oncology and hematology.

Key Points: 
  • Tubulis today announced the formation of a Scientific Advisory Board (SAB) with the appointment of international industry experts in the development of antibody drug conjugates (ADCs) and in-depth knowledge in the therapeutic areas of oncology and hematology.
  • Attracting these accomplished and highly regarded experts as inaugural members of our Scientific Advisory Board is a validation for our technological approach and maturation as a company, said Dr. Dominik Schumacher, CEO and co-founder of Tubulis.
  • Their combined expertise in oncology research, the ADC space and bringing novel, promising therapeutic approaches through clinical development, will be of great value.
  • Over the past 12 months, Dominik and his team have secured the financing, partnerships and team of experts that will enable the company to advance their unique ADC technology platforms toward clinical proof-of-concept, added Pamela Trail, PhD, Chairwoman of Tubulis Scientific Advisory Board.

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides a Business Update

Wednesday, September 22, 2021 - 9:05pm

Business highlights for the fourth quarter of fiscal year 2021 and recent weeks include the following:

Key Points: 
  • Business highlights for the fourth quarter of fiscal year 2021 and recent weeks include the following:
    Completed manufacturing of ANEB-001 capsules for upcoming Phase 2 clinical trial.
  • Operating expenses in the fourth quarter of fiscal 2021 were $2,484,705 compared with $173,351 in the same period in fiscal 2020.
  • Net loss in the fourth quarter of fiscal 2021 was $29,111,739, or $(1.59) per share, compared with a net loss of $174,637, or $(0.01) per share, in the fourth quarter of fiscal 2020.
  • Except as required by federal securities law, Anebulo Pharmaceuticals undertakes no obligation to update or revise forward-looking statements to reflect changed conditions.

AnHeart Therapeutics Announces Formation of Scientific Advisory Board

Wednesday, September 22, 2021 - 1:00pm

AnHeart Therapeutics (AnHeart), a clinical-stage global biopharmaceutical company committed to developing novel cancer therapies, announced today the formation of its Scientific Advisory Board (SAB) comprised of world-renowned oncologists to provide external scientific review and high-level counsel on the Companys research and development programs.

Key Points: 
  • AnHeart Therapeutics (AnHeart), a clinical-stage global biopharmaceutical company committed to developing novel cancer therapies, announced today the formation of its Scientific Advisory Board (SAB) comprised of world-renowned oncologists to provide external scientific review and high-level counsel on the Companys research and development programs.
  • We are excited and privileged to have the opportunity to work with this group of leading oncologists on the development of our pipeline, said Bing Yan, M.D., CMO and Co-founder of AnHeart Therapeutics.
  • We look forward to their continued contributions as AnHeart enters a new stage in advancing taletrectinib into late-stage clinical trials this year."
  • AnHeart is developing a broad pipeline of next-generation precision oncology therapeutics in areas of high unmet medical need.

IBCAP announces $24 million lawsuit against iStar IPTV service and its primary Michigan-based retailer, Atlas Electronics

Tuesday, September 21, 2021 - 7:08pm

This latest case comes on the heels of more than 20 successful lawsuits coordinated and supported by IBCAP over the last five years.

Key Points: 
  • This latest case comes on the heels of more than 20 successful lawsuits coordinated and supported by IBCAP over the last five years.
  • DISH Network, a member of IBCAP and the owner of exclusive rights that were infringed, filed this suit after multiple notices of infringement sent by IBCAP to iStar Company and Atlas Electronics were all ignored.
  • The claims include direct and indirect copyright infringement against iStar Company and Ahmed Karim and an indirect copyright infringement claim against Atlas Electronics and Alaa Al-Emara.
  • In total the lawsuit seeks damages of more than $24 million and injunctive relief.

BlueWillow Biologics Names Leading Viral Infectious Disease Experts to Scientific Advisory Board

Tuesday, September 21, 2021 - 12:00pm

BlueWillow Biologics, Inc. , a privately held clinical-stage biopharmaceutical company developing intranasal vaccines, today announced the formation of the Company's Scientific Advisory Board (SAB) with three leading viral infectious disease experts.

Key Points: 
  • BlueWillow Biologics, Inc. , a privately held clinical-stage biopharmaceutical company developing intranasal vaccines, today announced the formation of the Company's Scientific Advisory Board (SAB) with three leading viral infectious disease experts.
  • The members of the BlueWillow Biologics SAB include:
    Robin Isaacs, M.D.
  • Prior, he held positions of increasing responsibility at Merck & Co., Inc., most recently serving as Vice President and Therapeutic Area Head, Vaccine Clinical Research.
  • We are proud to have such a distinguished team of scientific experts serve as members of our Scientific Advisory Board, underscoring their belief in our intranasal vaccines to elicit mucosal immunity, commented Chad Costley, M.D., President and Chief Executive Officer of BlueWillow Biologics.

Lymphoma Research Foundation Celebrates 15 Years of its Annual Lymphoma Research Ride

Monday, September 20, 2021 - 5:00pm

BARNESVILLE, Md., Sept. 20, 2021 /PRNewswire-PRWeb/ -- The Lymphoma Research Foundation (LRF) the nation's largest non-profit organization dedicated exclusively to funding innovative lymphoma research and serving the lymphoma community through a comprehensive series of education programs, outreach initiatives, and patient services will host its 15th Annual Lymphoma Research Ride on Oct. 3, in Montgomery County, Md.

Key Points: 
  • BARNESVILLE, Md., Sept. 20, 2021 /PRNewswire-PRWeb/ -- The Lymphoma Research Foundation (LRF) the nation's largest non-profit organization dedicated exclusively to funding innovative lymphoma research and serving the lymphoma community through a comprehensive series of education programs, outreach initiatives, and patient services will host its 15th Annual Lymphoma Research Ride on Oct. 3, in Montgomery County, Md.
  • Over the past 15 years, the Lymphoma Research Ride has been a signature event as part of LRF's Team LRF community fundraising program and raised more than $6 million in support of LRF research programs and its support of the lymphoma community.
  • "We have a wonderful opportunity to bring the lymphoma community together through this nationwide program to share their stories and actively advocate for lymphoma research, support and education," said Meghan Gutierrez, Chief Executive Officer for the Lymphoma Research Foundation.
  • For more information about the Lymphoma Research Foundation's 15th Annual Lymphoma Research Ride or to register, contact Aileen Tapia at 646-465-9127 or visit lymphoma.org/researchride .

Rezolute Reports Fourth Quarter and Full Year Fiscal 2021 Financial Results and Highlights Recent Company Progress

Wednesday, September 15, 2021 - 9:56pm

Research and development (R&D) expenses were $4.4 million for the fourth quarter of fiscal 2021, compared to $2.4 million for the same period in fiscal 2020.

Key Points: 
  • Research and development (R&D) expenses were $4.4 million for the fourth quarter of fiscal 2021, compared to $2.4 million for the same period in fiscal 2020.
  • Full fiscal year 2021 R&D expenses were $15.0 million, compared to $14.5 million in fiscal year 2020.
  • General and administrative (G&A) expenses were $2.2 million for the fourth quarter of fiscal 2021, compared to $1.1 million for the same period in fiscal 2020.
  • Full fiscal year 2021 G&A expenses were $7.9 million, compared to $6.1 million in fiscal year 2020.

New Journal Article on the Challenges and Management of Sarcoidosis Supported by Foundation for Sarcoidosis Research

Wednesday, September 15, 2021 - 5:01pm

"Delayed diagnosis and lack of understanding of sarcoidosis are significant barriers to care for those living with sarcoidosis," says Mary McGowan, CEO for the Foundation for Sarcoidosis Research.

Key Points: 
  • "Delayed diagnosis and lack of understanding of sarcoidosis are significant barriers to care for those living with sarcoidosis," says Mary McGowan, CEO for the Foundation for Sarcoidosis Research.
  • Challenges of Sarcoidosis and Its Management is the first sarcoidosis scientific article published in NEJM since 2007 and is now considered the new standard of sarcoidosis review.
  • Despite increasing advances in research, sarcoidosis remains difficult to diagnose with limited treatment options and no known cure.
  • Established in 2000, The Foundation for Sarcoidosis Research (FSR) is the leading international nonprofit organization dedicated to finding a cure for sarcoidosis and improving care for sarcoidosis patients.

SAB Biotherapeutics Announces Completion of Enrollment in Phase 2a Challenge Trial of SAB-176 for the Treatment of Seasonal Influenza

Wednesday, September 15, 2021 - 12:00pm

SAB-176 is a novel anti-influenza human immunotherapy designed to address the limitations of current treatments for moderate to severe seasonal influenza.

Key Points: 
  • SAB-176 is a novel anti-influenza human immunotherapy designed to address the limitations of current treatments for moderate to severe seasonal influenza.
  • The Phase 2a clinical trial is a randomized, double-blind, placebo-controlled study that is evaluating the safety and treatment efficacy of SAB-176 in 60 healthy adults challenged with a pandemic influenza virus strain (pH1N1).
  • SAB-176 is also currently being evaluated in a Phase 1 ascending dose, double-blind, randomized, placebo-controlled safety trial in healthy volunteers, which has also completed enrollment.
  • SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies.